Posted by
Generic Medicines
The Generic Medicines Europe 2007 conference is to be held in the Radisson SAS Hotel, Berlin, Germany on 25-27 September 2007. The conference will examines the key issues, outages and strategies for success in the generics and biosimilars markets
Driving generics and biosimilars business strategies to the next level
- More hours of dedicated networking than any other generics event
- Troubleshoot challenges in regulation, litigation and accessing API
- Optimise your companies manufacturing and compliance capabilities
- Stay competitive; understand how business models are continually evolving in this sector
- The best mix of industry speakers from the pharmaceutical, generics, biotech, legal and non-for-profit sectors
Meet one of Fortune Magazines ‘Top 24 Innovators’
The May edition of Fortune magazine featured a special
article entitled ‘Innovators at the gate’. This focused on the work of 24
individuals who are doing their best to create new industries against all the
odds. Sunil Shaunak is Professor of
Infectious Diseases at
Professor Shaunak is an entrepreneur with a zeal for creativity and thinking outside the box. His key note address at Generic Medicines Europe 2007 promises to be both thought-provoking and an opportunity to look at new pharmaceutical horizons in the 21st Century. This will be an unmissable talk on ‘ethical pharmaceuticals’ and their potential to become a new driver for the pharmaceutical industry. Professor Shaunak and his colleague, Steve Brocchini from the London School of Pharmacy, already have a hepatitis C drug in clinical trials and have started work on a drug for leishmaniasis with funding from the Drugs for Neglected Diseases Initiative and the National Institutes of Health (USA).
Unmissable key addresses on the role of generics in the developing world
Alongside this talk, we have key addresses from several
other internationally recognised leaders who are also dedicated to addressing
key developing world disease treatment issues via strategic collaborations, IP,
the provision of cost-affordable medicines and generics. Speakers include Dr
Anthony So from
Generic Medicines Europe 2007 examines the key issues, outages and strategies for success in the generics and biosimilars markets. This is an unrivalled forum for discussing the latest updates in business model adaptation across the pharmaceutical industry, regulatory guidelines, manufacturing best practice, growth markets, pharmaceutical litigation and IP and accessing API. This is the definitive conference for leaders in the generics, biosimilars and non-profit sectors to meet, exchange ideas and network.
The
generics industry is booming. According to reports, the global generics market
is worth over $45bn and this is growing year on year. The loss of patent
protection for a number of lucrative drugs by 2010 will continue to drive this
exceptional market growth. The biosimilars market also looks set to be a key
future driver of the biopharmaceutical industry. Europe has already seen the
first regulatory approvals of biosimilar drugs and there is increasing government
pressure to repeat this in the
As competition in this sector continually increases and pricing pressure intensifies, companies must optimise their business strategies in order to remain competitive.
Traditional pharmaceutical companies are also adapting their business models in response to the generics boom, particularly through the use of ‘authorised generics’.
Therefore in order to maintain growth and profitability, generics companies must have excellent competitive intelligence, an understanding of strategic partnering and M&A, access to API and a continual understanding of updates in pharmaceutical legislation and regulation.
The biosimilars
sector is also facing a number of challenges which are restricting market
expansion. The release of regulatory guidelines for biosimilars in the
There are
also a number of manufacturing complexities which need to be addressed. Generic
Medicines Europe 2007 examines the key issues, outages and strategies for success
in the generics and biosimilars markets. This is an unrivalled forum for
discussing the latest updates in business model adaptation across the generics
industry, regulatory guidelines, manufacturing best practice, growth markets,
pharmaceutical litigation and IP and accessing API.
Who should attend?
If you fall into one of the industry categories below then Generic Medicines Europe 2007 is a must attend event for you. This meeting will show you how to troubleshoot the key industry issues and put you at the forefront of this dynamic market.
- Generics Pharmaceutical Manufacturers
- Traditional Pharmaceutical Manufacturers
- Biotechs
- Contract Manufacturing Organisations
- Contract Research Organisations
- Research Institutes
- Government and Regulatory Bodies
- Legal Practices
- Consultants